CD38 and systemic sclerosis: Thus, our study and the above mentioned reports prompt the use of anti-CD38 therapy in SSc; however, it is unclear whether the best approach would be the use of a cytotoxic monoclonal antibody or a reversible enzymatic inhibitor.